FDA’s Novel Approvals Again Led By Oncology And Neurology, But Dermatology Also Shone In 2022
Pink Sheet infographic breaks down the trends and surprises in 2022 approvals. Cancer therapies and non-malignant hematology exceeded the average use of expedited review programs but were weighted to orphan diseases, while dermatology saw first-in-class approvals for big markets.
You may also be interested in...
Pink Sheet infographic details the 20 complete response letters the US FDA issued for novel agents last year.
US FDA Neurology Drugs Program Gains Boost In FY 2023 Funding Bill Amid Calls To Clarify Development Policies
US FDA gains a nearly 7% increase in non-user fee funding, some of which will go for neurology drug guidance.
Lilly's Mounjaro and Roche's Vabysmo appear on track to be fast blockbusters in a year that saw the fewest drug launches since 2016.